Search
Now showing items 1-7 of 7
Design and optimization of nanoformulation loaded with HIV microbicides
(2013)
microscopy. The NP have an average mean diameter of 250 nm, maximal EE% of 16.1% and 37.2% for TNF and TDF, respectively. There is a 4-fold increase in drug release rate from the 75% S-100 NP in the presence of SFS over 72 h. At a concentration up to 10 mg...
Development of Protein Based PCBP2 siRNA Nanocomplex for Liver Fibrosis Therapy
(University of Missouri -- Kansas City, 2018)
The objective of this dissertation is to develop a protein-based siRNA
nanocomplex for the treatment of alcoholic liver fibrosis. Our laboratory recently
discovered that silencing the poly (rC) binding protein 2 (PCBP2) ...
Peptide-Based Platform For Cancer Therapeutics And Drug Transportation Across Blood-Brain Barrier
(University of Missouri -- Kansas City, 2018)
Prostate cancer is the most common male malignancy and remains the second-leading
cause of death due to cancer in American men. While surgery and radiation are effective in
prostate cancer therapy at early stages, the ...
Ritonavir - A Novel Multidrug Resistance Modulator in Cancer Chemotherapy and Ocular Neovascular Diseases
(2014-08-28)
Multidrug resistance (MDR), a clinical outcome characterized by subtherapeutic
intracellular drug concentration, is one of the predominant factors limiting effective cancer
chemotherapy. Several possible mechanisms and ...
Protein production and applications of NMR in pharmaceutical sciences
(2014-08-28)
The objective of Part I (Protein production for structural elucidation using NMR) is to design and develop strategies of producing amyloid beta protein for structural analysis using NMR. Amyloid beta oligomers are considered ...
Development of Advanced Delivery Systems for Microbicides
(2016)
HIV/AIDS still continues to be a pandemic and global emergency and is a leading cause of
death among the women of reproductive age (15-49 yr). Women are more vulnerable for HIV infection
due to anatomical and physiological ...
Development of Pentablock Copolymer Based Formulations for the Sustained Delivery of Protein Therapeutics in the Treatment of Posterior Segment Ocular Diseases
(2013)
have performed in vivo ocular tolerability studies with optimized PB formulations which demonstrated no inflammation, retinal toxicity, change in intraocular pressure or cataract even after 16 week of exposure. Moreover, in vivo studies further revealed...